专利检索 ap:("Merck Sharp & Dohme Corp.") AND inv:"Lei Chen" 第 1 页

1.

发明授权
Compounds that are ERK inhibitors 有权

公开(公告)号：US09233979B2

公开(公告)日：2016-01-12

申请号：US14431462

申请日：2013-09-26

申请人： Merck Sharp & Dohme Corp.

发明人： Kevin J. Wilson , David J. Witter , Phieng Siliphaivanh , Kathryn Lipford , David Sloman , Danielle Falcone , Brendan O'Boyle , Umar Faruk Mansoor , Jongwon Lim , Joey L. Methot , Christopher Boyce , Lei Chen , Matthew H. Daniels , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Ling Tong , Wei Zhou , Joseph Kozlowski , Milana M. Maletic , Bidhan A. Shinkre , Jayanth Thiruvellore Thatai , Raman Kumar Bakshi , Ganesh Babu Karunakaran

IPC分类号： C07D401/14 , A61K31/437 , C07D498/18 , C07D471/04 , A61K31/5377 , A61K31/496 , C07D471/14 , A61K31/4375 , C07D498/14 , A61K31/553 , C07D519/00 , A61K45/06

CPC分类号： C07D498/18 , A61K31/437 , A61K31/4375 , A61K31/496 , A61K31/5377 , A61K31/553 , A61K45/06 , C07D471/04 , C07D471/14 , C07D471/16 , C07D498/14 , C07D498/16 , C07D519/00 , A61K2300/00

摘要： Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).

2.

发明申请
HETEROCYCLE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 有权
标题翻译：杂环取代的四环化合物及其用于治疗病毒性疾病的方法

公开(公告)号：US20150335648A1

公开(公告)日：2015-11-26

申请号：US14761256

申请日：2013-12-31

申请人： MERCK SHARP & DOHME CORP.

发明人： Wensheng Yu , Ling Tong , Joseph A. Kozlowski , Oleg Selyutin , Lei Chen , Jae-Hun Kim , Deyou Sha , Razia Rizvi , Bandarpalle Shankar , Bin Hu , Bin Zhong , Dahai Wang , Jinglai Hao , Wei Wei , Tao Ji , Shuai Zan

IPC分类号： A61K31/5365 , C07D498/04 , C07D513/04 , A61K45/06

CPC分类号： A61K31/5365 , A61K31/4985 , A61K31/7056 , A61K31/7072 , A61K45/06 , C07D498/04 , C07D513/04 , Y02A50/385 , Y02A50/389 , A61K2300/00

摘要： The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3, R4 and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

摘要翻译： 本发明涉及式（I）的新型杂环取代的四环化合物：（I）及其药学上可接受的盐，其中A，A'，R 2 R3，R4和R如本文所定义。本发明还涉及包含至少一种杂环取代的四环化合物的组合物，以及使用杂环取代的四环化合物治疗或预防患者HCV感染的方法。

3.

发明授权
Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases 有权
标题翻译：杂环取代的四环化合物及其用于治疗病毒性疾病的方法

公开(公告)号：US09555038B2

公开(公告)日：2017-01-31

申请号：US14761256

申请日：2013-12-31

申请人： Merck Sharp & Dohme Corp.

发明人： Wensheng Yu , Ling Tong , Joseph A. Kozlowski , Oleg Selyutin , Lei Chen , Jae-Hun Kim , Deyou Sha , Razia Rizvi , Bandarpalle Shankar

IPC分类号： C07D498/04 , C07D513/04 , A61K31/5365 , A61K45/06 , A61K31/4985 , A61K31/7056 , A61K31/7072

CPC分类号： A61K31/5365 , A61K31/4985 , A61K31/7056 , A61K31/7072 , A61K45/06 , C07D498/04 , C07D513/04 , Y02A50/385 , Y02A50/389 , A61K2300/00

摘要： The present invention relates to novel Heterocycle-Substituted Tetracyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2 R3, R4 and R are as defined herein. The present invention also relates to compositions comprising at least one Heterocycle-Substituted Tetracyclic Compound, and methods of using the Heterocycle-Substituted Tetracyclic Compounds for treating or preventing HCV infection in a patient.

摘要翻译： 本发明涉及式（I）的新型杂环取代的四环化合物：（I）及其药学上可接受的盐，其中A，A'，R 2 R3，R4和R如本文所定义。本发明还涉及包含至少一种杂环取代的四环化合物的组合物，以及使用杂环取代的四环化合物治疗或预防患者HCV感染的方法。

4.

发明申请
THIOPHENE-SUBSTITUTED TETRACYCLIC COMPOUNDS AND METHODS OFUSE THEREOF FOR THE TREATMENT OF VIRAL DISEASES 审中-公开
标题翻译：噻吩取代的四环化合物及其用于治疗病毒性疾病的方法

公开(公告)号：US20160257697A1

公开(公告)日：2016-09-08

申请号：US14761259

申请日：2013-12-31

申请人： MERCK SHARP & DOHME CORP.

发明人： Ling Tong , Wensheng Yu , Joseph A. Kozlowski , Lei Chen , Oleg Selyutin , Seong Heon Kim , Michael Dwyer , Bin Hu , Bin Zhong , Dahai Wang , Jinglai Hao , Changmao Shen , Zhixin Lei , Weijun Wang

IPC分类号： C07D498/04 , C07D519/00 , A61K45/06 , A61K31/7056 , A61K31/7072 , A61K38/00 , A61K31/5365 , A61K38/21

CPC分类号： C07D498/04 , A61K31/4985 , A61K31/5365 , A61K31/7056 , A61K31/7072 , A61K38/005 , A61K38/212 , A61K45/06 , C07D519/00 , Y02A50/385 , Y02A50/387 , Y02A50/389 , Y02A50/395 , A61K2300/00

摘要： Thiophene-substituted tetracyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein A, A′, R2, R3, R4 and R5 are as defined herein. The compositions comprising at least one thiophene-substituted tetracyclic compound, and methods of using the thiophene-substituted tetracyclic compounds for treating or preventing HCV infection in a patient are also provided.

摘要翻译： 式（I）的噻吩取代的四环化合物及其药学上可接受的盐，其中A，A'，R 2，R 3，R 4和R 5如本文所定义。还提供了包含至少一种噻吩取代的四环化合物的组合物，以及使用噻吩取代的四环化合物治疗或预防患者HCV感染的方法。